The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 18th 2025
From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.
Long-Term Benefits of Cemiplimab Plus Chemotherapy Seen in Locally Advanced NSCLC
April 15th 2023A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.
Read More
Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL Persist
April 13th 2023Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.
Read More
Ixazomib Shows PFS Benefit Across Age and Frailty Subgroups in Multiple Myeloma
April 12th 2023A secondary analysis of the phase 3 TOURMALINE-MM4 trial found that ixazomib as postinduction maintenance therapy for multiple myeloma produced a progression-free survival (PFS) benefit vs a placebo across age and frailty subgroups.
Read More
Dr John Harris Discusses New Information Learned in Extension Studies for Ruxolitinib Cream
April 11th 2023Each trial extension has added new and more data and a better understanding of how ruxolitinib cream treats vitiligo in the long term, explained John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.
Watch
Biosimilars Can Create Huge Savings, but Interchangeability Needs to Be Reviewed
April 10th 2023A new report from AHIP indicates that biosimilars have the potential to garner savings of $180 billion over 5 years, but there needs to be a review of the approval process for interchangeability to encourage more approvals.
Read More
Dr Charles Wykoff: Some Patients May Need Both Gene Therapy and Anti-VEGF to Treat Wet AMD
April 10th 2023While there are benefits of gene therapy, some patients will continue to need anti–vascular endothelial growth factor (VEGF) therapy to treat wet age-related macular degeneration (AMD), said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.
Watch
Atopic Dermatitis Treatment Is Still More Trial and Error Than Personalized: Dr Emma Guttman-Yassky
April 9th 2023While the future is bright with potential for personalized medicine to treat atopic dermatitis, current treatment is still more like trial and error, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai.
Watch
DNA Sequencing Prior to HCT Identifies Patients at Risk of Poor AML Outcomes
April 8th 2023A study of patients with acute myeloid leukemia (AML) in first remission found that the presence of certain variants indicative of measurable residual disease ahead of allogeneic hematopoietic cell transplant (HCT) was associated with relapse and worse survival.
Read More
Sublobar Resection Produces Similar Outcomes to Lobectomy in Early NSCLC
April 5th 2023Patients who underwent sublobar resection and those who underwent more invasive lobectomy for early-stage non–small cell lung cancer (NSCLC) showed similar overall and disease-free survival outcomes in a recent study.
Read More